Centanafadine
- US: Investigational New Drug
- (1R,5S)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane
- 924012-43-1
- 16095349
- 17253639
- D2A6T4UH9C
- D10697 Y
- Interactive image
- C1=C(C=CC2=CC=CC=C12)[C@@]34C[C@@H]3CNC4
- InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1
- Key:HKHCSWPSUSWGLI-CABCVRRESA-N
Site | IC50 (nM) | Action | Ref |
---|---|---|---|
SERTTooltip Serotonin transporter | 83 nM | Blocker | [1] |
NETTooltip Norepinephrine transporter | 6 nM | Blocker | [1] |
DATTooltip Dopamine transporter | 38 nM | Blocker | [1] |
Centanafadine (INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with a ratio of 1:6:14, respectively.[1][2][3][4] In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance.[5][6] In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine.[7] As of January 2018, Otsuka's pipeline indicates it is in Phase II and III clinical trials for a number of different applications to medical conditions.[8][9][10]
See also
References
- ^ a b c d e "Neurovance's EB-1020 SR for Adult ADHD Shows Stimulant-Like Efficacy and Good Tolerability in Phase 2a Trial" (PDF). Neurovance. Retrieved 14 January 2018.
- ^ "3-Neurotransmitters, 1-Molecule: Optimized Ratios". Neurovance.
- ^ "EB-1020, a Non-Stimulant Norepinephrine and Dopamine - Preferring Reuptake Inhibitor for the Treatment of Adult ADHD" (PDF). Neurovance. Archived from the original (PDF) on 2015-11-17. Retrieved 2015-11-14.
- ^ Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI (June 2012). "Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder". Synapse. 66 (6): 522–32. doi:10.1002/syn.21538. PMID 22298359. S2CID 38850652.
- ^ "Euthymics". Ethismos Research Inc. Retrieved 14 January 2018.
- ^ "EUTHYMICS BIOSCIENCE, INC. PRESENTS DATA THAT SUPPORT ADVANCING EB-1020 INTO CLINICAL TRIALS FOR ADULT ADHD" (PDF). Neurovance. December 7, 2011. Retrieved 14 January 2018.
- ^ "Otsuka Pharmaceutical to Acquire Neurovance, Inc". Otsuka. Retrieved 14 January 2018.
- ^ "Otsuka U.S. Research & Development Programs". Otsuka U.S. Otsuka. Retrieved 14 January 2018.[permanent dead link]
- ^ Otsuka Pharmaceutical Development & Commercialization, Inc. (2021-09-17). "A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder".
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ Gunduz-Bruce H (2018-09-26). "SAGE-217 in major depressive disorder: a multicenter, randomized, double-blind, Phase 2 placebo-controlled trial". doi:10.26226/morressier.5b68175eb56e9b005965c44b. S2CID 266120058. Retrieved 2023-06-26.
External links
- Centanafadine - AdisInsight
- v
- t
- e
(DRIsTooltip Dopamine reuptake inhibitors)
(NRIsTooltip Norepinephrine reuptake inhibitors)
(SRIsTooltip Serotonin reuptake inhibitors)
- Amiodarone
- Amphetamines (e.g., amphetamine, methamphetamine, MDMA)
- APP
- AZIK
- Bietaserpine
- Deserpidine
- Deutetrabenazine
- Dihydrotetrabenazine
- Efavirenz
- GBR-12935
- GZ-793A
- Ibogaine
- Ketanserin
- Lobeline
- Methoxytetrabenazine
- Reserpine
- Rose bengal
- Tetrabenazine
- Valbenazine
- Vanoxerine (GBR-12909)
- DAT enhancers: Luteolin
- DAT modulators: Agonist-like: SoRI-9804
- SoRI-20040; Antagonist-like: SoRI-20041
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e